While most grasses go dormant or pause growth in the winter, not all weeds do - but which ones are most prevalent depends on ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food ...

Green Gobbler 20% Vinegar Weed Killer is a potent, nonselective vinegar-based product. It’s made from ethanol distilled from ...

Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

New federal testing data shows that reading scores of teens in the U.S. are lower than they have been in decades.

After years of volatility, crop protection is stabilizing. Discover where recovery, regulation, and innovation are reshaping ...

Zidesamtinib targets ROS1+ NSCLC patients with prior TKI treatment, addressing CNS-penetrant treatment challenges and ...

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

In the context of vocational English education, game-based teaching has emerged as a potential solution to address ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.